Our mission
MSInsight is empowering precision medicine in oncology by revealing actionable information on microsatellite instability – MSI – through genomic analysis.
Shape the future of the diagnosis of a tumoral biomarker at the genomic level,
Microsatellite Instability (MSI)
Unlock a deeper and more reliable identification of MSI with genomic data from Next-Generation Sequencing
Reveal actionable insights to better guide personalized treatment decisions and improve patient outcomes
Our expertise
MSInsight is providing state-of-the-art diagnostic solutions for MSI analysis in cancer patients and for therapeutic decision making
MSI cancers, for MicroSatellite Instable, are characterized
by genetic alterations in the repeated sequences of the DNA. This phenotype is
associated with nearly 4% of cancers worldwide.
MSI is a booming biomarker for immunotherapy response to
treatment prediction.
Resulting from 20 years of research on MSI tumor genetic and
bioinformatic, our technology enables to provide a more accurate and reliable
insight for MSI diagnosis using genomic data from Next-Generation Sequencing.
Our solution
We are leveraging the power of genomic data from NGS with best-in-class bioinformatic algorithms and AI solutions
Just upload your genomic data, we provide you the right information
Discover how our cutting-edge solution, MSIcare, is transforming the way MSI is detected and monitored in various types of solid cancers.
Who we are
At MSInsight, we bring together a team of dedicated experts in genomic, bioinformatic and oncology
Dr. Arnaud Cutivet
Dr .Toky Ratovomanana
Pr. Alex Duval
Olivier Exertier
Dr. Ada Collura
Dr. Florence Renaud
Our main partners
Pleasure to work with
They support us
We are backed by renowned start-up programs, institutions and public initiatives !
